Leandro Bueno Bergantin,Universidade Federal de São Paulo (Federal University of São Paulo), Department of Pharmacology
Rua Pedro de Toledo, 669 - EdifÃcio de Pesquisas II (7th floor) ? Funcionômica Laboratory
Vila Clementino
Postal Code: 04039032 - São Paulo, SP - Brazil
Biography
Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil) and UAM (Spain):
degree in biomedicine (2008), MSc (2010) and PhD (2014). His research involves cell signaling
mediated by Ca2+ and cAMP, skeletal and smooth muscles, peripheral and central nervous
systems. His research work solved the enigma of the paradoxical effects produced by Ltype
Ca2+ channel blockers (TOP 25 Hottest Articles - Biochemistry, Genetics and Molecular
Biology - Cell Calcium - TOP 1 July to September 2013/ TOP 5 October to December 2013/
TOP 1 January to December 2013 full year/TOP 6 January to March 2014). Since 1975,
several clinical and experimental studies have reported that acute and chronic administration of
L-type Ca2+ channel blockers (CCB), such as nifedipine, produces reduction in arterial pressure
associated with a paradoxical increase of sympathetic activity. Despite this sympathetic
hyperactivity has been initially attributed to adjust reflex of arterial pressure, the cellular and
molecular mechanisms involved in this apparent sympathomimetic effect of the L-type CCB
remained unclear for decades. In 2013, Dr. Bergantin and collaborators discovered that this
paradoxical increase in sympathetic activity produced by L-type CCB is due to interaction of
the Ca2+/cAMP signaling pathways. Then, the pharmacological manipulation of the Ca2+/cAMP
interaction produced by combination of the L-type CCB used in the antihypertensive therapy,
and cAMP accumulating compounds used in the antidepressive therapy, could represent a
potential cardiovascular risk for hypertensive patients due to increase in sympathetic activity. In
contrast, this pharmacological manipulation could be a new therapeutic strategy for increasing
neurotransmission in psychiatric disorders, and producing neuroprotection in the
neurodegenerative diseases (Bergantin and Caricati-Neto, 2016 Eur J Pharmacol; Caricati-Neto
et al., 2015 Pharm Res Perspect). Dr. Bergantin has published several articles in international
journals, book chapters, and an international book. He is member of editorial board of several
international journals.
Research Interest
Pharmacology & Toxicology, Toxicological Studies,Depression and Anxiety,Neurology and Neurosurgery,Brain Disorders & Therapy